Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDP-514 DDI Study with Itraconazole, Carbamazepine, and Quinidine
NCT04783753Phase 1Completed
- Sponsor
- Enanta Pharmaceuticals
- Start
- Nov 2020
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of EDP-514 in hepatitis B (HBV) (3 arms), sponsored by Enanta Pharmaceuticals. Primary endpoints: Cmax of EDP-514 with and without coadministration with itraconazole up to 19 days, AUC of EDP-514 with and without coadministration with itraconazole at 19 days and 4 more. Started Nov 2020; status: completed.
02
Drugs
EDP-514
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT04783753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04783753.